Penumbra, Inc. to Present at the Canaccord Genuity 41st Annual Growth Conference
Penumbra, Inc. (NYSE: PEN) will present at the Canaccord Genuity 41st Annual Growth Conference on August 11, 2021, at 11:00am ET / 8:00am PT.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Penumbra, Inc. (NYSE: PEN) will present at the Canaccord Genuity 41st Annual Growth Conference on August 11, 2021, at 11:00am ET / 8:00am PT. The event will showcase the company's innovative healthcare therapies aimed at addressing significant medical needs. Interested parties can access a webcast of the presentation via the investors' section of Penumbra's website, available for two weeks post-event. Penumbra operates primarily in the US, Europe, Canada, and Australia, focusing on cutting-edge products in the healthcare sector.
Details
News Market Reaction – PEN
The recorded move for PEN in the trading session of this news was +0.89%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ALAMEDA, Calif., July 28, 2021 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Canaccord Genuity 41st Annual Growth Conference on Wednesday, August 11, 2021.
Event: | Canaccord Genuity 41st Annual Growth Conference |
Date: | Wednesday, August 11, 2021 |
Time: | 11:00am ET /8:00am PT |
A webcast of the presentation will be available by visiting the investors' section of the company's website at www.penumbrainc.com. The webcast will be available on the company's website for at least two weeks following the event.
About Penumbra
Penumbra, Inc., headquartered in Alameda, California, is a global healthcare company focused on innovative therapies. Penumbra designs, develops, manufactures and markets novel products and has a broad portfolio that addresses challenging medical conditions in markets with significant unmet need. Penumbra sells its products to hospitals and healthcare providers primarily through its direct sales organization in the United States, most of Europe, Canada and Australia, and through distributors in select international markets. The Penumbra logo is a trademark of Penumbra, Inc. For more information, visit www.penumbrainc.com and connect on Twitter and LinkedIn.
Investor Relations
Penumbra, Inc.
510-995-2461
investors@penumbrainc.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/penumbra-inc-to-present-at-the-canaccord-genuity-41st-annual-growth-conference-301341371.html
SOURCE Penumbra, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.